The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation
Abstract
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51; Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013;34:2094-106]. Non-vitamin K antagonist oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Both physicians and patients have to learn how to use these drugs effectively and safely in clinical practice. Many unresolved questions on how to optimally use these drugs in specific clinical situations remain. The European Heart Rhythm Association set out to coordinate a unified way of informing physicians on the use of the different NOACs. A writing group defined what needs to be considered as 'non-valvular AF' and listed 15 topics of concrete clinical scenarios for which practical answers were formulated, based on available evidence. The 15 topics are (i) practical start-up and follow-up scheme for patients on NOACs; (ii) how to measure the anticoagulant effect of NOACs; (iii) drug-drug interactions and pharmacokinetics of NOACs; (iv) switching between anticoagulant regimens; (v) ensuring adherence of NOAC intake; (vi) how to deal with dosing errors; (vii) patients with chronic kidney disease; (viii) what to do if there is a (suspected) overdose without bleeding, or a clotting test is indicating a risk of bleeding?; (xi) management of bleeding complications; (x) patients undergoing a planned surgical intervention or ablation; (xi) patients undergoing an urgent surgical intervention; (xii) patients with AF and coronary artery disease; (xiii) cardioversion in a NOAC-treated patient; (xiv) patients presenting with acute stroke while on NOACs; and (xv) NOACs vs. VKAs in AF patients with a malignancy. Additional information and downloads of the text and anticoagulation cards in >16 languages can be found on an European Heart Rhythm Association web site (www.NOACforAF.eu).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–241 of 241
Abdulhak, A. A. B., Khan, A. R., Tleyjeh, I. M., Spertus, J. A., Sanders, S. U., Steigerwalt, K. E., Garbati, M. A., Bahmaid, R. A., & Wimmer, A. P. (2013) · EP Europace · doi:10.1093/europace/eut239 · Cited by 66
How Long After Drug Ingestion Is Activated Charcoal Still Effective?
Green, R. S., Grierson, R., SITAR, D. S., & Tenenbein, M. (2001) · Journal of Toxicology Clinical Toxicology · doi:10.1081/clt-100108492 · Cited by 66
Roldán, V., Cancio, S., Gálvez, J., Valdés, M., Vicente, V., Marín, F. R., & Lip, G. Y. H. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.036 · Cited by 66
Best Practice for Atrial Fibrillation Patient Education
Lane, D. A., Barker, R., & Lip, G. Y. H. (2014) · Current Pharmaceutical Design · doi:10.2174/1381612820666140825125715 · Cited by 65
Steinberg, B. A., Hellkamp, A. S., Lokhnygina, Y. V., Halperin, J. L., BREITHARDT, G. E., PASSMAN, R. S., Hankey, G. J., Patel, M. R., Becker, R. C., Singer, D. E., et al. (2014) · Heart Rhythm · doi:10.1016/j.hrthm.2014.03.006 · Cited by 64
Self-citationLarsen, T. B., Nielsen, P. B., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114445 · Cited by 64
Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban
Frost, C. E., Shenker, A., Gandhi, M. D., Pursley, J. M., Barrett, Y. C., Wang, J. J. J., Zhang, D., Byon, W., Boyd, R. A., & LaCreta, F. P. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12393 · Cited by 63
Kaess, B. M., Ammar, S., Reents, T., Dillier, R., Lennerz, C., Semmler, V., Grebmer, C., Bourier, F. J., Buiatti, A., Kolb, C., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.10.005 · Cited by 62
Proietti, M., & Lip, G. Y. H. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv012 · Cited by 62
Bertoméu, V., Cequier, A. R., Marín, F. R., Anguita, M. P., & Ortiz, M. R. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-02-0169 · Cited by 61
Moore, K. T., Plotnikov, A. N., Thyssen, A., Vaccaro, N. M., Ariyawansa, J., & Burton, P. B. J. (2011) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e31822f6c2b · Cited by 59
Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation
Nielsen, P. B., Larsen, T. B., Gorst‐Rasmussen, A., Skjøth, F., Rasmussen, L. H., & Lip, G. Y. H. (2014) · CHEST Journal · doi:10.1378/chest.14-2099 · Cited by 59
Abumuaileq, R. R.-Y., Abu-Assi, E., Raposeiras‐Roubín, S., López-López, A., Diéguez, A. R., Álvarez-Iglesias, D., Rodríguez‐Mañero, M., Peña, C., & González‐Juanatey, J. R. (2015) · EP Europace · doi:10.1093/europace/euu353 · Cited by 59
Stangier, J., Stähle, H., Rathgen, K., Roth, W., Reseski, K., & Körnicke, T. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270010393342 · Cited by 58
Vranckx, P., Verheugt, F. W. A., de Maat, M. P. M., Ulmans, V., Regar, E. S., Smits, P., ten Berg, J. M., Lindeboom, W. K., Jones, R., Friedman, J., et al. (2013) · EuroIntervention · doi:10.4244/eijv8i9a162 · Cited by 56
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2012) · Journal of International Medical Research · doi:10.1177/030006051204000508 · Cited by 53
LaHaye, S. A., Gibbens, S. L., Ball, D. G. A., Day, A. G., Olesen, J. B., & Skanes, A. C. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs167 · Cited by 53
Efficacy and Safety of Apixaban in the Patients Undergoing the Ablation of Atrial Fibrillation
Nagao, T., Inden, Y., Shimano, M., Fujita, M., Yanagisawa, S., Kato, H., Ishikawa, S., Miyoshi, A., OKUMURA, S., Ohguchi, S., et al. (2014) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.12553 · Cited by 50
Lip, G. Y. H. (2008) · BMJ · doi:10.1136/bmj.39351.706586.ad · Cited by 49
Transition of Patients From Blinded Study Drug to Open-Label Anticoagulation
Ruff, C. T., Giugliano, R. P., Braunwald, E., Mercuri, M. F., Curt, V., Betcher, J., Grip, L. T., Cange, A. L., Crompton, A. E., Murphy, S. A., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.028 · Cited by 48
Aryal, M. R., Ukaigwe, A., Pandit, A., Karmacharya, P., Pradhan, R., Mainali, N. R., Pathak, R., Jalota, L., Bhandari, Y., & Donato, A. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.05.038 · Cited by 47
Vranckx, P., Leebeek, F. W. G., Tijssen, J. G. P., Koolen, J., Stammen, F., Herman, J.-P., de Winter, R. J., Hof, A. V. T., Backx, B., Lindeboom, W. K., et al. (2015) · Thrombosis and Haemostasis · doi:10.1160/th15-01-0061 · Cited by 47
Heidbüchel, H., Berti, D., Campos, M., Desteghe, L., Freixo, A. P., Nunes, A. R., Roldán, V., Toschi, V., & Lassila, R. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0046-0 · Cited by 46
Interventional Thrombectomy for Major Stroke — A Step in the Right Direction
Hacke, W. (2014) · New England Journal of Medicine · doi:10.1056/nejme1413346 · Cited by 43
Self-citationEffect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
Upreti, V. V., Song, Wang, Byon, Boyd, Pursley, LaCreta, & Frost (2013) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s41999 · Cited by 40
Cutler, T., Chuang, A., Huynh, T. D., Witt, R. G., Branch, J. M., Pon, T. K., & White, R. (2014) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2014.20.10.1028 · Cited by 40
Sardar, P., Nairooz, R. S., Chatterjee, S., Wetterslev, J., Ghosh, J., & Aronow, W. S. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.12.027 · Cited by 39
Warfarin Use and Outcomes in Patients with Atrial Fibrillation Complicating Acute Coronary Syndromes
Lópes, R. D., Starr, A. Z., Pieper, C. F., Al‐Khatib, S. M., Newby, L. K., Mehta, R. H., de Werf, F. V., Mahaffey, K. W., Armstrong, P. W., Harrington, R. A., et al. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.09.015 · Cited by 39
Potpara, T., Lip, G., Dagres, N., Estner, H., Larsen, T., & Blomström-Lundqvist, C. (2014) · Europace · doi:10.1093/europace/euu008 · Cited by 38
Proposed Approach to Thrombolysis in Dabigatran-Treated Patients Presenting with Ischemic Stroke
Kate, M. P., Szkotak, A. J., Witt, A., Shuaib, A. M., & Butcher, K. (2014) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.11.013 · Cited by 35
Shurrab, M., Morillo, C. A., Schulman, S., Kansal, N., Danon, A., Newman, D. M., Lashevsky, I., Healey, J. S., & Crystal, E. (2013) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2013.07.005 · Cited by 26
Fiedler, K. A., Byrne, R. A., Schulz, S., Sibbing, D., Mehilli, J., Ibrahim, T., Mæng, M., Laugwitz, K., Kastrati, A., & Sarafoff, N. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.01.005 · Cited by 22
Getta, B. M., Muller, N., Motum, P., Hsu, D. C., Zebeljan, D., & Rosenfeld, D. (2014) · British Journal of Haematology · doi:10.1111/bjh.13236 · Cited by 22
Fauchier, L., Angoulvant, D., & Lip, G. Y. H. (2015) · EP Europace · doi:10.1093/europace/euv088 · Cited by 22
Verso, M., Agnelli, G., & Prandoni, P. (2015) · Internal and Emergency Medicine · doi:10.1007/s11739-015-1233-5 · Cited by 19
Pfeilschifter, W., Abruscato, M., Hövelmann, S., & Baas, H. K. J. (2013) · Case Reports in Neurology · doi:10.1159/000350570 · Cited by 18
Non-Vitamin K Antagonist Oral Anticoagulants
Lip, G. Y. H., Camm, A. J., Hylek, E. M., et al. (2014) · CHEST Journal · doi:10.1378/chest.13-2951 · Cited by 17
Self-citationPatient Guide for Taking the Non–Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation
Lane, D. A., & Wood, K. (2015) · Circulation · doi:10.1161/circulationaha.114.012808 · Cited by 17
“R” for “Renal” and for “Risk”
Camm, A. J., & Savelieva, I. (2013) · Circulation · doi:10.1161/circulationaha.112.147512 · Cited by 15
Self-citationAbstracts From the Emerging Science Series, June 20, 2012
(2012) · Circulation · doi:10.1161/cir.0b013e3182611cc2 · Cited by 14
Beriplex P/N reverses bleeding in an acute renal injury model after dabigatran overdose in rabbits
Pragst, I., Dörr, B., Kaspereit, F., et al. (2012) · F1000Research · doi:10.7490/f1000research.1089950.1 · Cited by 13
Research works printed but not linked: 23
- 10.1160/TH14-06-0564 · doi:10.1160/th14-06-0564
- 10.1016/S0735-1097(14)60325-9 · doi:10.1016/s0735-1097(14)60325-9
- Matsushima N Lee F Sato T Weiss D Mendell J . Absolute Bioavailability of Edoxaban in Healthy Subjects. The AAPS Journal 2011;13 (Suppl):S2. (abstract).
- Frost C Yu Z Nepal S Bragat A Moore K Shenker A Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. J Clin Pharmacol 2008;48:1132 (abstract).
- Vakkalagadda B Frost C Wang J Nepal S Schuster A Zhang D Effect of rifampicin on the pharmacokinetics of apixaban, on oral direct inhibitor of factor Xa. J Clin Pharmacol 2009;49:1124 (abstract).
- Frost C Boyd RA . The contribution of apixaban renal clearance to total clearance. J Thromb Thrombolysis 2015; doi:10.1007/s11239-015-1220-8 doi:10.1007/s11239-015-1220-8. · doi:10.1007/s11239-015-1220-8
- Kubitza D Becka M Zuehlsdorf M Mueck W . No interaction between the novel, oral direct factor Xa inhibitor BAY 59-7939 and digoxin. J Clin Pharmacol 2006;46:702 (Abstract 11). · DOI · Paper page
- 10.1111/bcp.12075 · DOI · Paper page
- 10.1124/dmd.113.053769 · doi:10.1124/dmd.113.053769
- Mendell J Noveck R Zahir H Lee F Petrushin V Rubets I The effect of quinidine and verapamil, P glycoprotein/CYP3A4/5 inhibitors, on edoxaban pharmacokinetics and pharmacodynamics. Basic Clin Pharmacol Toxicol 2010;107:2848. (Abstract).
- Pan X Kachroo S Liu X Kawabata H Phatak H . Discontinuation among early users of apixaban, dabigatran, rivaroxaban or warfarin among atrial fibrillation patients newly initiated on anticoagulation therapy: tale of first 200 days. Eur Heart J 2014;35 (Abstract Supplement):897. · doi:10.1016/s0735-1097(14)60415-0
- Chang M Shenker A Wang J Yu Z Pursley J Boyd R Apixaban pharmacokinetics and pharmacodynamics in subjects with renal impairment. Clin Pharmacol Drug Dev 2012;1:185.
- Ridout G de la Motte S Niemczyk S Sramek P Johnson L Jin J Effect of renal function on edoxaban pharmacokinetics (PK) and on population PK/PK-PD model. J Clin Pharmacol 2009;49:1124. (abstract).
- 10.1016/j.cjca.2014.01.015 · doi:10.1016/j.cjca.2014.01.015
- Wang X Tirucherai G Ehlgen A Wang J Chang M Zhang D Apixaban pharmacokinetics in subjects with end-stage renal disease on hemodialysis. Clin Pharmacol Drug Dev 2012;1:187.
- Perlstein I Wang Z Song Y Wang J Bedford B Chang M Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects. Blood 2014;124:345. · doi:10.1182/blood.v124.21.345.345
- 10.1093/europace/eut296 · doi:10.1093/europace/eut296
- 10.1093/europace/eut353 · doi:10.1093/europace/eut353
- 10.1016/j.amjcard.2012.12.046 · DOI
- Jennings JM Robichaux R McElderry HT Plumb VJ Gunter A Doppalapudi H Cardiovascular implantable electronic device implantation with uninterrupted dabigatran: comparison to uninterrupted warfarin. J Cardiovasc Electrophysiol 2013;24:1125–9. · doi:10.1111/jce.12214
- 10.1093/europace/eut423 · doi:10.1093/europace/eut423
- 10.1007/s003920050171 · doi:10.1007/s003920050171
- 10.1016/j.ahj.2014.12.020 · DOI
Cited by
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab670 · Cited by 19,442
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Ponikowski, P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González-Juanatey, J. R., Harjola, V.-P., Jankowska, E. A., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw128 · Cited by 11,429
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · Europace · doi:10.1093/europace/euw295 · Cited by 6,439
Self-citation2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS
Kirchhof, P., Benussi, S., Kotecha, D., Ahlsson, A., Atar, D., Casadei, B., Castella, M., Diener, H.-C., Heidbuchel, H., Hendriks, J., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw210 · Cited by 6,418
Self-citation2017 ESC/EACTS Guidelines for the management of valvular heart disease
Baumgartner, H., Falk, V., Bax, J. J., De Bonis, M., Hamm, C., Holm, P. J., Iung, B., Lancellotti, P., Lansac, E., Rodriguez Muñoz, D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx391 · Cited by 6,243
Metadata
- Authors
- Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Diener, H.-C., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P.
- Venue
- Europace
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-31
- Volume
- 17
- Issue
- 10
- Pages
- 1467-1507
- ISSN
- 1099-5129 (ISSN-L)
- 1532-2092
- OpenAlex
- W1834574045
- Cited by
- 1,113
- References
- 241
- FWCI
- 151.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- Bayer Pharma AG
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Pfizer Alliance and Daiichi-Sankyo Europe
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.